| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Z-Val-Gly-OH does not have a specific biological target as a drug. Its primary utility is as a chemical building block in peptide synthesis. The compound serves as a protected valine-glycine dipeptide unit that can be incorporated into peptide chains. The Val-Gly sequence may be recognized by certain proteases, but in its protected form, the compound is not designed to interact with biological receptors or enzymes for therapeutic purposes. Its value lies in its chemical properties as a synthetic intermediate.
|
|---|---|
| ln Vitro |
Z-Val-Gly-OH does not exhibit pharmacological activity in vitro. As a protected dipeptide derivative, it is a synthetic intermediate rather than a bioactive compound. In vitro studies using this compound focus on its chemical reactivity in peptide bond formation reactions, rather than assessments of pharmacological activity. The compound may be used as a substrate in enzymatic assays to study protease specificity, but these are analytical applications. Its role in research is almost exclusively as a reagent for organic synthesis.
|
| ln Vivo |
Z-Val-Gly-OH is not a pharmacologically active compound and therefore does not have defined in vivo activity as a drug. When administered to animals, the compound would likely be metabolized to release valine and glycine, which would then enter normal metabolic pathways. However, the compound is not used therapeutically. Its primary value remains in synthetic chemistry, where it serves as a building block for the preparation of peptides and pharmaceutical compounds.
|
| Enzyme Assay |
In vitro enzyme assays for Z-Val-Gly-OH are primarily focused on studying protease or peptidase activity. A standard protocol involves incubating the compound with an enzyme preparation in a suitable buffer at physiological pH and temperature. The hydrolysis of the dipeptide bond releases valine and glycine derivatives, which can be quantified by HPLC or mass spectrometry. The progress of the reaction can be monitored, and kinetic parameters such as Km and Vmax can be determined. These assays are used to characterize the substrate specificity of proteases.
|
| Cell Assay |
In vitro cellular assays using Z-Val-Gly-OH are not commonly performed because the compound lacks intrinsic biological activity. The compound is used exclusively in synthetic chemistry applications and is not designed for cell culture studies. Its use is confined to the laboratory, where it serves as a building block for the preparation of peptides and pharmaceutical compounds.
|
| Animal Protocol |
In vivo animal studies with Z-Val-Gly-OH are not typically conducted, as the compound is a synthetic intermediate rather than a pharmacologically active agent. If used in vivo, the compound would be administered to animals to study the metabolism of protected dipeptide derivatives. However, such studies are rare, and the compound is generally used exclusively in synthetic chemistry applications.
|
| ADME/Pharmacokinetics |
Z-Val-Gly-OH is not a drug candidate, and pharmacokinetic data are not available. As a protected dipeptide derivative, it is designed for chemical synthesis rather than systemic administration. If administered in vivo, the compound would likely be metabolized to release valine and glycine. The compound's pharmacokinetic properties have not been characterized.
|
| Toxicity/Toxicokinetics |
The compound is generally considered to have low toxicity, consistent with its use as a chemical reagent. Standard laboratory safety precautions, including the use of personal protective equipment, are recommended. It is not classified as a highly toxic substance, but appropriate safety measures should be followed. Inhalation, ingestion, or skin contact should be avoided.
|
| Additional Infomation |
Z-Val-Gly-OH (CAS 2790-84-3) is a protected dipeptide building block used in peptide synthesis. It features a Z (benzyloxycarbonyl) protecting group on the N-terminus and consists of L-valine and glycine. It is intended for research use only and is not for human therapeutic applications.
|
| Molecular Formula |
C15H20N2O5
|
|---|---|
| Molecular Weight |
308.33000
|
| Exact Mass |
308.137
|
| CAS # |
2790-84-3
|
| PubChem CID |
7005167
|
| Appearance |
White to off-white solid powder
|
| Density |
1.226g/cm3
|
| Boiling Point |
577ºC at 760 mmHg
|
| Flash Point |
302.8ºC
|
| Vapour Pressure |
3.73E-14mmHg at 25°C
|
| Index of Refraction |
1.538
|
| LogP |
1.92
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
22
|
| Complexity |
391
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC([C@H](NC(OCC1=CC=CC=C1)=O)C(NCC(O)=O)=O)C
|
| InChi Key |
MWOJWUBBCZRMTB-ZDUSSCGKSA-N
|
| InChi Code |
InChI=1S/C15H20N2O5/c1-10(2)13(14(20)16-8-12(18)19)17-15(21)22-9-11-6-4-3-5-7-11/h3-7,10,13H,8-9H2,1-2H3,(H,16,20)(H,17,21)(H,18,19)/t13-/m0/s1
|
| Chemical Name |
2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2433 mL | 16.2164 mL | 32.4328 mL | |
| 5 mM | 0.6487 mL | 3.2433 mL | 6.4866 mL | |
| 10 mM | 0.3243 mL | 1.6216 mL | 3.2433 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
